en · de · es · pt
hplc-notes.peptides9002.com › Info › Tirzepatide �ˆ†子背景与靶点 — Hands-On Walkthrough

Tirzepatide �ˆ†子背景与靶点 — Hands-On Walkthrough

By Editorial Desk · published 2026-02-19 · last reviewed 2026-04-04 · Info

If you have been reading about incretin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-04-04. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强,从而延长循环半衰期,支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征,减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用,属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

Dual Incretin Receptor Pharmacology

At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.

Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

Tirzepatide at a glance

PropertyValueNotes
分子类型合成修饰肽39 个氨基酸,含脂肪酸侧链
受体靶点GIP 与 GLP-1 受体双重激动剂
分子量约 4.8 kDa以游离肽计
外观白色至类白色粉末冻干形态常见
溶解性可溶于水及水性缓冲液溶解后宜低温保存

Molecular Background and Dual Receptor Action

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.

Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Related pages on this site

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Molecular Background and Receptor Pharmacology

Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Analytical Methods And Storage Stability

The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.

Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.

Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.

Reference notes

The Cytochrome C assembles an apoptosome which activates the Caspase-9 and initiates an executioner Caspase cascade, effectively breaking down DNA into histones and promoting apoptosis. [6]-Gingerol also inhibits the anti-apoptotic Bcl-2 proteins on the surface of mitochondria, which in turn increases the capabilities for the pro-apoptotic Bcl-2 proteins to initiate cell death. Cancer cells exhibit high amounts of growth hormone activator proteins that are expressed through enzyme-coupled signaling pathways. By halting the phosphorylation of PI-3-Kinase the Akt protein cannot bind with its PH domain, effectively deactivating the downstream signal. Successively keeping Bad proteins bound to anti-apoptotic proteins which keeps them from promoting cell growth, consequently, a double negative cellular signaling pathway to promote apoptosis. Cultured human breast cancer cells were subjected to various concentrations of [6]-gingerol to determine the impacts on live cells. These concentration dependent results concluded that there was no impact at 5 μM but a reduction of 16% occurred at 10 μM. [6]-gingerol targeted three specific proteins in breast cancer cells that promote metastasis and while adhesion remained relatively unchanged, [6]-gingerol inhibited the cancer cells from invading and increasing in size. This study suggests the mechanism by which cancer cell growth was impacted was due to a reduction in specific mRNA that transcribes for extracellular degrading enzymes called matrix metalloproteinases (MMP's).

The unit of measurement used to describe the ribosomal subunits and the rRNA fragments is the Svedberg unit, a measure of the rate of sedimentation in centrifugation rather than size. This accounts for why fragment names do not add up: for example, bacterial 70S ribosomes are made of 50S and 30S subunits. Prokaryotes have 70S ribosomes, each consisting of a small (30S) and a large (50S) subunit. E. coli, for example, has a 16S RNA subunit (consisting of 1540 nucleotides) that is bound to 21 proteins. The large subunit is composed of a 5S RNA subunit (120 nucleotides), a 23S RNA subunit (2900 nucleotides) and 31 proteins.

When the Atlantic slave trade began, many of the local slave systems began supplying captives for chattel slave markets outside Africa. Although the Atlantic slave trade was not the only slave trade from Africa, it was the largest in volume and intensity. As Elikia M'bokolo wrote in Le Monde diplomatique:

Locals are called "Subordinate Assemblies"; the national "Supreme Assembly" meets quadrennially, board of directors runs things in between those. Headquarters in Philadelphia. Slovak Catholic Sokol - Founded in 1905 as the Roman and Greek Catholic Union; a gymnastic society much like Sokol USA, but with a stronger religious, Catholic emphasis, including financial assistance to missionaries and people preparing for the priesthood. Sponsors annual track and field event. In 1921 had 19,025 members, more than 42,000 in 1936, 44,243 in 1946, and 50,000 in 1979. 50,000 members in 1995. Headquarters in Passaic, New Jersey. Slogan: "Sound mind in a sound body in a sound society". Motto: Za boha a narod, "For God and Nation". Patron saint Martin of Tours. Had 25% million in assets in 1921; attended 26th International Eucharistic Congress; gives out 20 scholarships of $500 per year. Sokol U.S.A. - A Sokol movement, apparently popular among people of Czech and Slovak descent in the mid-19th century. The earliest antecedent of this particular organization was a lodge founded in 1896, full name Slovak Gymnastic Union Sokol of the United States of America. Sponsors gymnastic events called Slets, insurance benefits, dances and calisthenics, scholarships, and "camps and halls" in several states. 23,000 members in 1979, and 12,000 in 1995. Absorbed the Slovak Evangelical Society and the Tatran Slovak Union in 1944. United Lutheran Society - Traces its origins to the Slovak Evangelical Union founded in 1893 in Freeland, Pennsylvania. In 1906 the Evangelical Slovak Women's Union was founded.

Sources: en.wikipedia.org

Reference notes

==== Refrigeration ==== Food storage in refrigerators may not be safe unless there is close adherence to temperature guidelines. In general, the temperature should be maintained at 4 °C (39 °F) or below, but never below 1 °C (34 °F). Safe storage times vary by food and may depend on how the food was handled before being placed in the refrigerator.

In the 2024 presidential election, Americans aged 18 to 29 voted for Kamala Harris by a margin of only four points, according to exit polls conducted by the Associated Press. Donald Trump and his Republican Party made considerable gains among young voters, especially young men and European Americans. Among Gen-Z women, while those of ethnic-minority backgrounds overwhelmingly supported Harris, those of European ancestry were evenly split between Harris and Trump. This election has broken the historical trend of young people generally voting for Democrats. Generation Z has been shifting towards the right since 2020. Even so, polls conducted after that election showed that the majority of Generation Z disapproved of the performance of President Donald Trump because he had failed to address their concerns about the economy, especially inflation and the cost of living.

by correcting the error – entering a new value for example or when the datapoint is updated by marking the variable as correct – some EDC systems required additional response or you can raise a further query if you are not satisfied with the response

Sources: en.wikipedia.org

Frequently asked questions

Tirzepatide 属于哪一类分子?

它属于合成修饰肽,同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂,与选择性 GLP-1 激动剂在靶点范围上不同。

为什么它只需每周给药一次?

分子上的脂肪酸侧链使其与血浆白蛋白结合增强,显著延长循环半衰期。半衰期延长后,稳定血药浓度可在较长的给药间隔内维持,因此常见用法为每周一次。

双靶点设计的意义是什么?

同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比,临床研究中观察到的血糖与体重变化幅度通常更明显,但各通路的具体贡献比例尚无定论。

What class of compound is tirzepatide?

It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.

Network